Radioiodine decision after thyroid surgery for intermediate-risk cancer
Part of Cancer, Hormones & metabolism clinical trials.
This study compares two approaches after thyroid surgery: giving radioactive iodine right away versus deciding based on follow-up test results. It aims to see which approach better helps people with intermediate-risk differentiated thyroid cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have differentiated thyroid cancer (papillary, follicular, or Hürthle cell), not medullary/anaplastic/poorly differentiated, and not NIFTP.
- Your cancer must be “intermediate-risk” based on specific tumor size/lymph node details and limited spread (and no extra growth outside the capsule).
- You had total thyroidectomy with all visible tumor removed (no R2/microscopic leftover that counts as incomplete).
- You had surgery 6 to 10 weeks (about 1–2.5 months) before randomization, and started thyroid hormone (levothyroxine/LT4) at least 6 weeks before enrolling.
- Your post-surgery neck ultrasound looks normal; if something was unclear, follow-up testing must be negative and tumor marker Tg must be under 10 ng/mL.
- You have no known distant metastases and you can attend yearly follow-ups for 5 years; performance status must be 0 or 1 (able to do most usual activities).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial offers a decision aid to help you choose whether to have radioactive iodine (RAI) treatment after thyroid cancer surgery. You may qualify if you have intermediate-risk thyroid cancer and haven't yet made a decision about RAI.
This study looks at how well radioactive iodine therapy works for patients with certain types of thyroid cancer that are considered low or intermediate risk. It may help you understand if this treatment is right for you.
This trial is testing whether giving radiation therapy after thyroid surgery can help destroy any leftover cancer cells in people with high-risk differentiated thyroid cancer. It is for those who had surgery but some cancer was still left behind.
This study looks at whether adding radiation therapy after surgery can help people with thyroid cancer that is at high risk of coming back. It includes different types of thyroid cancer, like differentiated and medullary types.
This study looks at how different doses of radioactive iodine work for people with papillary or follicular thyroid cancer after their thyroid has been removed. It aims to find the best dose to treat the cancer while reducing side effects.
This study collects information on how redifferentiation medicines used before radioactive iodine work in everyday care for certain thyroid cancers that are unlikely to respond to radioactive iodine. It may help doctors understand the best real-world way to use these medicines to plan and deliver treatment.
Hear when a new Thyroid Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.